MRVI
Maravai Lifesciences Hldgs-A
NASDAQ · Life Sciences Tools & Services
$3.14
+0.05 (+1.62%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 480.58M | 699.53M | 284.80M | 273.78M | 251.69M |
| Net Income | -268,568,801 | -351,836,857 | 25.98M | 28.90M | 28.85M |
| EPS | — | — | — | — | — |
| Profit Margin | -55.9% | -53.1% | 9.1% | 10.6% | 11.5% |
| Rev Growth | -31.3% | -31.3% | -1.9% | +20.4% | +17.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 201.51M | 201.51M | 414.08M | 416.02M | 343.21M |
| Total Equity | 199.95M | 199.95M | 294.41M | 328.29M | 334.51M |
| D/E Ratio | 1.01 | 1.01 | 1.41 | 1.27 | 1.03 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -442,398,250 | -611,758,860 | 47.22M | 49.69M | 44.12M |
| Free Cash Flow | — | — | 23.78M | 29.47M | 28.71M |